General Information of the Compound
Compound ID
CP0026322
Compound Name
N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
    Show/Hide
Synonyms
N-[((R)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide
N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
PD 0325901
PD 325901
PD-0325901
PD-325901
PD0325901
PD325901
S06-0029
    Show/Hide
Structure
Formula
C16H14F3IN2O4
Molecular Weight
482.196
Canonical SMILES
OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F
    Show/Hide
InChI
InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1
    Show/Hide
InChIKey
SUDAHWBOROXANE-SECBINFHSA-N
CAS
391210-10-9
Physicochemical Property
logP
2.4667
Rotatable Bonds
7
Heavy Atom Count
26
Polar Areas
90.82
Hydrogen Bond Donor Count
4
Hydrogen Bond Acceptor Count
5
Complexity
26

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 9826528
SID: 14785709
ChEMBL ID
CHEMBL507361
DrugBank ID
DB07101
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01476, Mitogen-activated protein kinase kinase kinase 8
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000012 Sf21 Spodoptera frugiperda (Fall armyworm)  1
1
IC50 > 25000 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( PD-0325901 )
Drug Name PD-0325901
Company Pfizer
Indication
Breast cancer
Phase 2